Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.

Kidney Res Clin Pract · 2012 · PMC4716095 · PMID 26894018

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP =0.06so close (0.05 < p ≤ 0.1)

The increase in TKV between baseline and 2 years was lower in the everolimus group versus the placebo, but did not reach statistical significance ( P =0.06).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.